Dec. 03, 2025 -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application (“NDA”) meeting minutes from the U.S. Food and Drug Administration (“FDA”) supporting the NDA submission of D-PLEX100, the Company’s lead product candidate for the prevention of surgical site infections in abdominal colorectal surgeries. The FDA agreed that the Company’s existing cli

Nov. 24, 2025 -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced the publication of clinical and translational data from a Phase Ib study (NCT03594422) on the Company’s novel drug, olverembatinib (HQP1351), in patients with gastrointestinal stromal tumors (GIST), b

Nov. 26, 2025 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present one oral late breaking communication and two poster presentations featuring blarcamesine at t

Nov. 25, 2025 -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy. Macomics’ ENIGMAC drug discovery platform is designed to discover therapeutic targets and unlock disease specific target biology. The platform enables identification and validation of novel targets and provides a translationally relevant path to the clinic through the development of more physiologically relevant human models co

AMX-883 shows synergistic efficacy in combination with venetoclax in vivo and prevents the emergence of resistance to venetoclax in vitro, addressing a major clinical challenge in acute myeloid leukaemia (AML) AMX-883 showed a significant survival benefit and reduced disease burden compared to control treatments, while being well tolerated in a murine pre-clinical experiment Data provides compelling evidence of BRD9's critical role in AML and supports progression of AMX-883, as a karyotype-indep

Nov. 19, 2025 -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes an article in Nature Communications establishing circular single-stranded DNA (CssDNA) as a highly efficient non-viral DNA donor template, for gene insertion in hematopoietic stem and progenitor cells (HSPCs). Gene editing of HSPCs offers the potential for long-term t

Nov. 18, 2025 -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a business update and reported its financial results for the third quarter 2025. “The third quarter was marked by solid and positive clinical and operational execution. Our clinical, manufacturing and regulatory teams are heavily focused on moving Ampligen down a pathway toward eventual FDA approval as part of a combination therapy for pancreatic cancer. We recently reported positive mid-year safe

Nov. 17, 2025 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 26th Annual Meeting of the Society of Urologic Oncology (SUO) taking place from December 2, 2

Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company’s Alzheimer's Disease clinical trial results Nov. 14, 2025 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including

–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– Nov. 03, 2025 -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing cell and exosome-based therapies for rare diseases, today announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro potency assay designed to characterize the anti-fibroti